Safety and Quality of Life of CDK4/6 Inhibitors Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Cross-Sectional Survey in China

    May 2025 in “ BMC Cancer ”
    Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Linxiaoxi Ma, Hao‐Qi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xuming Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu
    TLDR CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
    This study surveyed 1,254 Chinese patients with hormone receptor-positive, HER2-negative advanced breast cancer undergoing treatment with CDK4/6 inhibitors, primarily dalpiciclib, abemaciclib, and palbociclib. Adverse events were reported in over 81% of patients, with leukopenia and neutropenia being the most frequent. Alopecia incidence was lower in patients treated with dalpiciclib compared to palbociclib and abemaciclib, and it significantly impacted body image and quality of life. The study concludes that the safety and quality of life impacts of CDK4/6 inhibitors vary, emphasizing the need for careful consideration in clinical practice to optimize treatment strategies and improve quality of life.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results